Drug Trial Radar · NCT02689284
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Jan 2016
Primary completion
Jan 2021
Study completion Jan 2021
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Feb 23, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This main purpose of this clinical study is to learn about the safety and activity of margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and gastroesophageal junction cancer.
Conditions
- Gastric Cancer
- Stomach Cancer
- Esophageal Cancer
Interventions
Margetuximab 10 mg/kgBiological
Margetuximab treatment is administered intravenously (IV) once every 21-day cycle
Margetuximab 15 mgBiological
Margetuximab treatment is administered IV once every 21-day cycle
PembrolizumabBiological
Pembrolizumab treatment is administered IV once every 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Dose Limiting ToxicitiesTime frame: 21 days
- Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs).Time frame: up to 24 months
- Number of Patients With a Complete Response (CR) or Partial Response (PR) to TreatmentTime frame: 12 months
- Number of Patients With a Complete Response (CR) or Partial Response (PR) to Treatment Using irRC CriteriaTime frame: 12 Months
- Duration of ResponseTime frame: up to 24 months
Locations
28 sites in 5 countries. Site status is shown where the registry gives one.
Yale School of Medicine
New Haven, Connecticut
Georgetown University-Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia
University of Chicago
Chicago, Illinois
Johns Hopkins University Medical Center
Baltimore, Maryland
Dana-Farber Cancer Institute/Harvard University Medical Center
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
Duke University Medical Center
Durham, North Carolina
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
Swedish Cancer Institute
Seattle, Washington
Juravinski Cancer Centre - McMaster University
Hamilton, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
National Cancer Centre
Singapore, Singapore
National University Hospital
Singapore, Singapore
Raffles Hospital
Singapore, Singapore
Kyungbuk National University Hospital
Daegu, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
Chonbuk National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Bundang Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Tri-Service General Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.